Compare Hilton Hotels Corporation Common Stock (HLT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Mesoblast Limited — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.76 (market cap $72.76B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 41.6× Mesoblast Limited's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Mesoblast Limited for 14 Days on average.
| HLT | MESO | |
|---|---|---|
Market Cap | $72.76B | $1.75B |
Volume | 1,148,634 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $20.96 |
52-Week Low | $256.96 | $13.19 |
Typical Hold Time | 138 Days | 14 Days |
Enterprise Value | $85.78B | $1.83B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $320.50, down 0.65% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates consistent revenue growth, reaching $12.04 billion in 2025, with earnings beating expectations for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 57% buy ratings and a $348.11 consensus price target representing 8.6% upside potential. Recent institutional buying activity and upcoming Q3 2026 earnings on October 27 provide near-term catalysts.
Hilton presents a compelling investment case with robust fundamentals and positive momentum, though elevated valuation metrics (P/E of 47.07) and increasing debt levels warrant caution. The stock's technical positioning near key support at $318 suggests potential for continued upward movement if earnings momentum persists, while institutional accumulation and strong travel demand support the bullish thesis.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
